is semaglutide fda approved for mash Approval Expands Novo Nordisk's Wegovy to the Fatty Liver Disease FDA Grants Accelerated Approval of

Patients should be instructed on the importance of rotating injection sites, monitoring blood glucose levels if applicable, and seeking medical attention if they experience any concerning symptoms or adverse reactions

The STEP 1 obesity trial gives a sense of the scale of the effect: The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5

Are some people at higher risk for dehydration on GLP-1 treatments

I find Wegovy in Appendix A by name as well

These risks can be listed as follows: Although rare, some people may experience mild allergic reactions such as redness and stomach cramps

Additionally, dosing errors with compounded products can cause more severe symptoms than would occur with properly dosed medication